Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study

The Lancet Oncology

Volumn 14, Issue 13, 2013, Pages 1348-1356

  Younes, Anas ^a   Connors, Joseph M ^b   Park, Steven I ^c   Fanale, Michelle ^a   O'Meara, Megan M ^d   Hunder, Naomi N ^d   Huebner, Dirk ^e   Ansell, Stephen M ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d SEATTLE GENETICS INC   (United States)

^e TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTIGEN DETECTION; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHILL; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; HYPERURICEMIA; INSOMNIA; LEUKOPENIA; LIMB PAIN; LUNG EMBOLISM; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RASH; RHINORRHEA; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME; VINBLASTINE;

EID: 84888138217     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70501-1     Document Type: Article

References (24)

1. Harel S, Ferme C, Poirot C Management of fertility in patients treated for Hodgkin's lymphoma. Haematologica 2011, 96:1692-1699.
2. Connors JM State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005, 23:6400-6408.
3. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report form a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752.
4. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013, 31:684-691.
5. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009, 27:805-811.
6. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012, 379:1791-1799.
7. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011, 365:203-212.
8. Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 1972, 77:861-870.
9. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003, 21:607-614.
10. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009, 27:5390-5396.
11. Younes A, Gopal AK, Smith SC, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30:2183-2189.
12. McEarchern JA, Kennedy D, McCormick R, et al. Activity of SGN-35 in preclinical models of combination therapy and relapse prevention. Haematologica 2010, 95(suppl). abstr 17.
13. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
14. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicenter trials in Hodgkin lymphoma. Eur J Nucl Med 2010, 37:1824-1833.
15. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013, 54:683-690.
16. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005, 23:7614-7620.
17. Canellos GP, Duggan D, Johnson J, Niedzwiecki D How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?. J Clin Oncol 2004, 22:1532-1533.
18. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005, 23:9198-9207.
19. Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's Disease. J Clin Oncol 2007, 25:3902-3907.
20. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359:2065-2071.
21. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
22. Clinical practice guidelines in oncology: Hodgkin lymphoma v 2.2013 National Comprehensive Care Network, (accessed Sept 30, 2013). http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf.
23. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk adapted BEACOPP regimen can reduce the cumulative dose chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007, 109:905-909.
24. Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial. Haematologica 2010, 95(suppl). abstr 1146.